Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3948 |
Name | adrenocortical carcinoma |
Definition | An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer adrenal gland cancer adrenal cortex cancer adrenocortical carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 amp | Derazantinib | adrenocortical carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01898715 | Phase I | ATR-101 | Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma | Completed | USA | DEU | 0 |
NCT02720484 | Phase II | Nivolumab | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | Terminated | USA | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
NCT03333616 | Phase II | Ipilimumab + Nivolumab | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | Recruiting | USA | 0 |
NCT03370718 | Phase II | Cabozantinib | Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma | Active, not recruiting | USA | 0 |
NCT03612232 | Phase II | Cabozantinib | Cabozantinib in Advanced Adrenocortical Carcinoma (CaboACC) | Recruiting | DEU | 0 |
NCT04187404 | Phase Ib/II | EO2401 + Nivolumab | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (Spencer) | Recruiting | USA | ITA | FRA | ESP | DEU | 3 |
NCT04373265 | Phase I | Pembrolizumab + Relacorilant | Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production | Recruiting | USA | 0 |
NCT04400474 | Phase II | Atezolizumab + Cabozantinib | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) | Active, not recruiting | ESP | 0 |
NCT04544995 | Phase I | Dostarlimab-gxly + Niraparib | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors | Recruiting | GBR | FRA | ESP | DEU | 2 |
NCT05634577 | Phase II | Mitotane + Pembrolizumab | A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma | Recruiting | USA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advance Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |